Bariatric Surgery Remains Cost-Effective Despite Rise of GLP-1 Medications
Despite the growing popularity and perceived convenience of GLP-1 agonists for weight loss, metabolic and bariatric surgery remains a more economical and cost-effective long-term solution for obesity, according to leading experts in the field.This consensus emerged during discussions at the International Federation for the surgery of Obesity and Metabolic Disorders (IFSO)’s 2025 World Congress in Santiago,Chile.
“We may not be as sexy anymore, but we’re cheaper,” a phrase coined by Ricardo Cohen, president of the IFSO, encapsulated the prevailing sentiment among attendees. The remark highlights a critical consideration as healthcare systems grapple with the escalating costs associated with the latest anti-obesity medications.
While pharmacologic treatments have gained significant traction, surgical approaches continue to offer a durable and financially beneficial alternative. david Cummings, MD, professor of medicine in the Division of Metabolism, Endocrinology, and Nutrition at the University of Washington in Seattle, emphasized the long-term cost benefits of bariatric surgery. Cummings,whose research focuses on the hormonal regulation of appetite and metabolism,noted that the initial investment in surgery is often offset by reduced healthcare expenses related to obesity-associated comorbidities over time.
The shift in perception comes as GLP-1 agonists – and similar drugs – experience a surge in demand. These medications, while effective for weight loss, require ongoing prescriptions and represent a substantial recurring expense for patients. Bariatric surgery, conversely, offers a possibly one-time intervention with lasting effects.
The debate isn’t about choosing one approach over another, but rather recognizing the distinct roles each plays in addressing the complex issue of obesity. Experts acknowledge that GLP-1 agonists can be valuable tools, particularly for individuals who are not suitable candidates for surgery or as a bridge to surgery. Though, the long-term economic realities favor surgical interventions for many patients.
The IFSO World Congress underscored the need for a nuanced approach to obesity treatment, one that considers both clinical efficacy and economic sustainability. As the healthcare landscape evolves, the value proposition of bariatric surgery is poised to become increasingly apparent.
